Phase I dose-escalation study of the tolerability and pharmacokinetics of a weekly 24h infusion of rigosertib in patients with advanced solid tumours.

Trial Profile

Phase I dose-escalation study of the tolerability and pharmacokinetics of a weekly 24h infusion of rigosertib in patients with advanced solid tumours.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Rigosertib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Onconova Therapeutics
  • Most Recent Events

    • 23 Feb 2012 Actual initiation date (June 2006), additional lead investigator (Sridhar Mani) and actual patient no 42 added as reported by ClinicalTrials.gov.
    • 23 Feb 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
    • 23 Feb 2012 Actual end date (November 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top